BACKGROUND: Triggering receptor expressed on myeloid cells-1 (TREM-1) is one of the more recently described biomarkers for sepsis and currently of great interest, as an inhibitor called nangibotide (Inotrem, Paris, France) for TREM-1 has made it into a phase 3 study for the treatment of sepsis. This evidence concerns the gene TREM1 and Sepsis.